Results 161 to 170 of about 152,178 (350)

Trastuzumab deruxtecan for breast cancer: do patients experience a comprehensive benefit? [PDF]

, 2023
Fernanda Mosele, Massimo Di Maïo
openalex   +1 more source

Novel Liquid Biopsy in Gastrointestinal Cancers

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Gastrointestinal (GI) cancers represent a significant global health burden, being among the leading causes of cancer‐related deaths. The prognosis for patients remains unsatisfactory, largely because most cancers are detected at advanced stages.
Li‐Chun Chang, Tang‐Long Shen, Takahiro Ochiya   +2 more
wiley   +1 more source

Eficacia de la combinación de Vinorelbine- Trastuzumab en carcinoma de mama metastásico con sobreexpresión de HER2, previamente tratado con Trastuzumab [PDF]

, 2013
L'addició de Trastuzumab a quimioteràpia basada en taxans millora la supervivència de les pacients amb carcinoma de mama metastàtic i sobreexpressió de HER2.
Cortés, Javier, Rodríguez Freixinós, Víctor, Suriñach Caralt, Josep Mª, Universitat Autònoma de Barcelona. Departament de Medicina, Universitat Autònoma de Barcelona. Facultat de Medicina   +4 more
core  

The Association Between Circadian Disruption in Core Body Temperature Rhythm and Post‐Chemotherapy Sleep Disturbances in Breast Cancer Survivors

Journal of Sleep Research, EarlyView.
ABSTRACT Sleep disturbance is a common symptom experienced by approximately 70% of breast cancer survivors and persists after the conclusion of chemotherapy. This study aimed to quantify the circadian disruption of the core body temperature (CBT) rhythm and its correlation with sleep disturbance following chemotherapy.
Joon Sung Shin, Sanghyup Jung, Geun Hui Won, Sun Hyung Lee, Jaehyun Kim, Saim Jung, Chan‐Woo Yeom, Kwang‐Min Lee, Kyung‐Lak Son, Jang‐il Kim, Sook Young Jeon, Han‐Byoel Lee, Bong‐Jin Hahm   +12 more
wiley   +1 more source

Antibody-antigen interactions: What is the required time to equilibrium? [PDF]

, 2010
The use of antibodies is widespread in many areas including in-vivo and in-vitro diagnostics, quantitative analysis in research laboratories and as therapeutic substances.
Hanna Bjö, Karl Andersson, Magnus Malmqvist   +2 more
core   +1 more source

GAS7 is differentially expressed in the primary tumors of breast cancer patients treated with trastuzumab.

, 2020
Shahan Mamoor
openalex   +1 more source

Cardio-Oncology Risk Assessment and Management in Patients Receiving Pertuzumab and Trastuzumab: Case Report and Literature Review [PDF]

, 2022
Lalitha C. Medepalli
openalex   +1 more source

Postexercise muscle oxygen uptake kinetics in older breast cancer survivors and healthy individuals: Association with myosteatosis

Experimental Physiology, EarlyView.
Abstract Reduced cardiorespiratory fitness is common among breast cancer survivors and, although traditionally attributed to cardiac dysfunction, might also be related to peripheral skeletal muscle abnormalities. We examined peak and submaximal plantar‐flexion exercise and recovery kinetics for lower‐leg oxygen uptake (V̇O2${\dot V_{{{\mathrm{O}}_2}}}$)
Nathan R. Weeldreyer, Thomas J. McMurtry, Stephen J. Foulkes, Amanda Shewman, Edith Pituskin, Rachel J. Skow, Richard B. Thompson, Justin Grenier, Deirdre E. O'Neill, Robert C. Welsh, Mark J. Haykowsky, Corey R. Tomczak   +11 more
wiley   +1 more source

A Case of Human Epidermal Growth Factor Receptor 2‐Positive Colon Cancer With Invasive Micropapillary Carcinoma Component

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT A female patient in her 60s tested positive for the fecal occult blood test while undergoing health screening. Colonoscopy revealed a 15‐mm‐sized flat elevated lesion with a central depression in the sigmoid colon. Narrow‐band imaging magnification revealed a Japan Narrow‐Band Imaging Expert Team classification of type 2B, whereas crystal ...
Masashi Kono, Yoriaki Komeda, Hiroshi Kashida, Satoru Hagiwara, Akihiro Yoshida, Shunsuke Omoto, Mamoru Takenaka, Naoko Tsuji, George Tribonias, Masatoshi Kudo   +9 more
wiley   +1 more source

Endoscopic Complete Response to Zolbetuximab for Advanced Gastric Cancer With Claudin 18.2 Positive: A Case Report

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Recently, zolbetuximab combined with chemotherapy has been approved as a first‐line treatment for advanced gastric cancer (GC). However, to date, no endoscopic images demonstrating endoscopic complete response (eCR) to zolbetuximab plus chemotherapy have been reported.
Akinori Sasaki, Tomohiro Yamaba, Ayu Tachibana, Rika Kimura, Gaku Uchiyama, Tsubasa Yoshioka, Risa Okamoto   +6 more
wiley   +1 more source